Article thumbnail

Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver

By Fatemeh Abedini, Maznah Ismail, Hossein Hosseinkhani, Tengku Azmi Tengku Ibrahim, Abdul Rahman Omar, Pei Pei Chong, Mohd Hair Bejo and Abraham J Domb

Abstract

Liver metastasis is the main cause of mortality related to colorectal cancer. CXCR4 is necessary for the outgrowth of colon cancer micrometastases. In oncology, it has been demonstrated that several human tumors release lactate dehydrogenase (LDH) into the circulation. CXCR4 gene expression and serum LDH levels are often increased in patients with colorectal cancer. Despite technological advances in cancer therapy, five-year overall survival is still around 50%. Therefore, better treatment needs to be developed. RNA interference (RNAi) is a modern and powerful tool for inhibition of gene expression. However, the rate-limiting step in this technology is effective delivery of RNAi agents. We have investigated a novel strategy of CXCR4 siRNA therapy and its effect on serum LDH levels in a BALB/C mouse model of colorectal cancer metastasis to the liver. Hepatic metastasis was established by injecting a CT26.WT mouse colon carcinoma cell line via the tail vein. Our results demonstrated that CXCR4 siRNA/ dextran-spermine nanoparticles achieved high silencing efficiency with low toxicity. Favorable localization of the nanoparticles was confirmed with CXCR4 gene expression in the liver, that was correlated with serum LDH levels. More research will be needed to determine the effect of CXCR4 silencing on serum LDH levels, which may be a useful marker for predicting liver metastasis in colorectal cancer

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3173020
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). Cancer incidence, mortality and survival data.
  2. (1993). Cancer-cell traffic in the liver.
  3. Dextran- sperminebased polyplexes – Evaluation of transgene expression and of local and systemic toxicity in mice.
  4. (2003). Dextran-spermine conjugate: An efficient vector for gene delivery. Macromolecular Symposia.
  5. Dextran-spermine polycation: An efficient non-viral vector for in vitro and in vivo gene transfection. Gene Ther.
  6. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.
  7. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther.
  8. Manipulating the chemokine-chemokine receptor network to treat cancer.
  9. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2’-deoxyuridine.
  10. Novel dextran-spermine conjugates as transfecting agents: Comparing water-soluble and micellar polymers. Gene Ther.
  11. Polysaccharide-oligoamine based conjugates for gene delivery.
  12. (2005). Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res.
  13. Specific inhibition of gene expression by small doublestranded RNAs in invertebrate and vertebrate systems.
  14. (1998). The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
  15. The hemodynamic destruction of circulating cancer cells.
  16. (2005). The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med.
  17. (1999). Treatment of colorectal liver metastases.